Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Nov 28, 2023

Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's...

Read more news from CSL

Recent News Releases
Jun 20, 2023

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus...

Read more news from CSL Behring

Recent News Releases
Sep 26, 2023

CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...

Read more news from CSL Seqirus

Recent News Releases
Nov 24, 2023

Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of...

Read more news from CSL Vifor

Read all company news releases

Media Contacts

Victoria, Australia
Phone: +61 450 909 211

CSL Behring
North America


Asia Pacific

CSL Seqirus
EMEA and Latam
Emmanuella Dekonor
Phone: +44 7920500496

North America
Tiffany Cody
Phone: +1 908 370 1863

Asia Pacific
Hamish Walsh
Phone: 0422 424 338

CSL Plasma
United States

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • facebook icon
  • instagram icon
Get our latest news releases in your inbox
* Required Fields